Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Phase I, Open-Label, 3-period Crossover study to evaluate the ffect of food on the Safety, Tolerability and PK of an IR tablet formulation of Lefamulin in Healthy male subjects

Next Previous
Trial Profile

A Single-center, Phase I, Open-Label, 3-period Crossover study to evaluate the ffect of food on the Safety, Tolerability and PK of an IR tablet formulation of Lefamulin in Healthy male subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lefamulin (Primary)
  • Indications Bacterial infections; Bone and joint infections; Community-acquired pneumonia; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections; Skin and soft tissue infections
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 12 Apr 2019 New trial record
  • 01 Apr 2019 Results assessing the pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing in four studies (NCT01119105, NCT02557789, EudraCT2012-004404-35 and EudraCT2012-000025-50) published in the Journal of Antimicrobial Chemotherapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top